Ask AI
ProCE Banner Activity

Individualizing Treatment Strategies in Multiple Myeloma: From Risk Assessment to Supportive Care

Clinical Thought

In this commentary, oncology pharmacists James A. Davis, PharmD, BCOP and Kelley L. Julian, PharmD, BCOP, review contemporary treatment strategies across the multiple myeloma continuum, including risk-adapted management of high-risk smoldering myeloma, evolving frontline approaches, and the growing role of anti-CD38–based therapies. The discussion highlights MRD-guided decision-making, supportive care considerations, and the importance of individualized, patient-centered treatment planning to optimize outcomes and quality of life.

Released: July 10, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients with high-risk smoldering MM on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Apply pharmacist-led strategies to mitigate and manage adverse events related to anti-CD38–based treatments for MM

Financial Disclosures

Primary Author

James A. Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, GSK, Janssen.

Kelley L. Julian, PharmD, BCOP: consultant/advisor/speaker: GSK, Johnson & Johnson, Pfizer.